– Invitae adds chief commercial officer to
leadership team; Innovative leader to help expand market share and
drive revenue growth –
SAN
FRANCISCO, Aug. 28, 2023 /PRNewswire/ --
Invitae (NYSE: NVTA), a leading medical genetics company,
today announced that it has appointed Robert (Rob) Guigley as its chief commercial
officer, effective September 5, 2023.
Mr. Guigley brings to the role more than 20 years of commercial
experience spanning biotechnology, pharmaceuticals, diagnostics and
genetic testing. He will develop and implement Invitae's commercial
strategy with a focus on driving profitable revenue growth,
expanding the market, improving reimbursement levels and enhancing
the service of clients and patients.
"I'm excited to welcome Rob to the leadership team as we sharpen
our focus on expanding the size and number of pathways for
profitable growth," said Ken Knight,
president and chief executive officer of Invitae. "Rob is a
talented and innovative leader who has provided vision and led
impactful change throughout his career. His deep understanding of
the long-term prospects of genetic information, along with his
extensive experience working with payers, make him the perfect
choice to help guide the next phases of our journey."
Mr. Guigley has led direct sales and marketing campaigns in a
variety of roles. Most recently, he served as chief commercial
officer at Ambry Genetics, responsible for executing their
commercial strategy and overseeing commercial sales, business
development, client services, managing genetic specialists and
expanding market access.
Mr. Guigley began his career in pharmaceutical sales at
AstraZeneca, giving him a strong foundation in selling to
physicians. He then migrated into diagnostics, leading sales and
market access at Quest Diagnostics and Counsyl. Mr. Guigley earned
his MBA at Boston University Questrom
School of Business and his BS at the University of Pittsburgh, where he focused on
economics, math and philosophy.
"I'm excited to be joining Invitae and for the opportunity to
support its mission to bring comprehensive genetic information into
mainstream medicine," said Rob
Guigley, incoming chief commercial officer for Invitae. I'm
looking forward to using my passion for patients and broad
experience to develop an innovative commercial strategy for
Invitae."
Inducement Grant
Pursuant to his hiring as the
Company's chief commercial officer, Invitae is granting 850,000
restricted stock units ("RSUs") to Rob
Guigley under Invitae's 2015 Stock Incentive Plan (the "2015
Plan"), which will be amended and restated to add 850,000 shares of
Invitae common stock to a pool of shares under the 2015 Plan which
is to be used exclusively for the grant of inducement awards in
compliance with New York Stock Exchange Rule 303A.08 ("Rule
303A.08"). The RSUs, which were subject to approval by Invitae's
Board of Directors, are being granted as an inducement material to
Mr. Guigley's agreement to be employed with Invitae in reliance on
the employment inducement exemption under Rule 303A.08. One-third
of the RSUs will vest on each of the first three anniversaries of
August 15, 2023, subject to Mr.
Guigley's continued service as an employee of Invitae through the
applicable vesting dates. The grant of the RSUs is subject to the
terms and conditions of the 2015 Plan and the applicable form of
stock award agreement.
About Invitae
Invitae (NYSE: NVTA) is a leading
medical genetics company trusted by millions of patients and their
providers to deliver timely genetic information using digital
technology. We aim to provide accurate and actionable answers to
strengthen medical decision-making for individuals and their
families. Invitae's genetics experts apply a rigorous approach to
data and research, serving as the foundation of their mission to
bring comprehensive genetic information into mainstream medicine to
improve healthcare for billions of people.
To learn more, visit invitae.com and follow for updates on
Twitter, Instagram,
Facebook and LinkedIn @Invitae.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to the appointment of Mr. Guigley as the company's new
chief commercial officer. Forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ
materially, and reported results should not be considered as an
indication of future performance. These risks and uncertainties
include, but are not limited to: the company's ability to grow its
business in a cost-efficient manner; the company's history of
losses; the company's ability to maintain important customer
relationships; the company's ability to compete; the company's
failure to manage growth effectively; the company's need to scale
its infrastructure in advance of demand for its tests and to
increase demand for its tests; risks associated with litigation;
the company's ability to use rapidly changing genetic data to
interpret test results accurately and consistently; security
breaches, loss of data and other disruptions; laws and regulations
applicable to the company's business; and the other risks set forth
in the company's filings with the Securities and Exchange
Commission, including the risks set forth in the company's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2023. These forward-looking statements
speak only as of the date hereof, and Invitae Corporation disclaims
any obligation to update these forward-looking statements.
Invitae Contacts:
Investor Relations
Hoki
Luk
ir@invitae.com
Public Relations
Amy
Hadsock
pr@invitae.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invitae-hires-industry-veteran-robert-guigley-as-chief-commercial-officer-301911496.html
SOURCE Invitae Corporation